Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21901862 | 0.91 | SIRT5 (0.31) | SIRT5 | |
| SCHEMBL24722146 | 0.91 | SIRT5 (0.34) | SIRT5SIRT2 | |
| SCHEMBL19170464 | 0.85 | SIRT5 (0.31) | SIRT5 | |
| SCHEMBL19203552 | 0.83 | SIRT5 (0.40) | SIRT5MAPTHSD17B10SIRT2MEN1 | |
| SCHEMBL18272909 | 0.81 | GLP1R (0.35) | — | |
| SCHEMBL18272906 | 0.81 | GLP1R (0.35) | — | |
| SCHEMBL19767723 | 0.81 | GLP1R (0.35) | — | |
| SCHEMBL19171240 | 0.81 | SIRT5 (0.37) | SIRT5MAPTHSD17B10SIRT2MEN1 | |
| SCHEMBL18272904 | 0.80 | GLP1R (0.34) | — | |
| SCHEMBL19170423 | 0.80 | NMT2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-9950076-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | SIRT5 3045/4885MAPT 3597/4885HSD17B10 1426/4885 |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | HNMT, SLC10A1, SLC10A2 | SIRT5 2864/4885MAPT 3410/4885HSD17B10 1309/4885 |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | SIRT5 3045/4885MAPT 3597/4885HSD17B10 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.